Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

May 19, 2025

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically

American Thoracic Society (ATS) 2025
Read More
May 17, 2025

Revolutionizing Immunology: Oral Medicines with Biologics-like Activity

American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
Read More
March 8, 2025

Clinical and Translational Science: Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults

Agarwal, et al.
Read More
October 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

American College of Allergy, Asthma & Immunology (ACAAI) 2024
Read More
September 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

European Academy of Dermatology and Venereology (EADV) 2024
Read More
August 16, 2024

Journal of Medicinal Chemistry: Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases

Zheng, et al.
Read More
July 29, 2024

Journal of Investigative Dermatology: Interleukin 1 Receptor–Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers

McDonald, et al.
Hidradenitis Suppurativa (HS)
Read More
May 22, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a House Dust Mite Model of Asthma

American Thoracic Society (ATS) 2024
Read More
May 21, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation In Vivo in a Mouse Model

Digestive Disease Week (DDW) 2024
Read More
March 8, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a Mouse Model of Atopic Dermatitis

American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More